Our group is dedicated to relevant clinical questions related to melanoma and other skin conditions. During this year we have discovered important metabolic treats associated to second-most predominant form of cutaneous malignant melanoma, that lacks a specific line of treatment. Importantly, this discovery has led to the design of novel therapeutic strategy generating a synthetic lethal condition that make these tumors sensitive to sorafenib; an FDA approved drug. In addition to this, we also have contributed to the description of novel genetic variants of proteins that mediate the immune response in melanoma that might have an impact in the antitumoral response, and the development of algorithms to calculate the risk of getting melanoma in transplanted patients.

Group Leader
Juan Angel Recio Conde, Vicente García-Patos Briones

Kimberley MacGrail, Carlos González Cruz

PhD Students
Paula Granado Martínez, Yuxin Ding, Berta Ferrer










McGrail K, Granado-Martínez P, Esteve-Puig R, García-Ortega S, Ding Y, Sánchez-Redondo S, Ferrer B, Hernandez-Losa J, Canals F, Manzano A, Navarro-Sabaté A, Bartrons R, Yanes O, Pérez-Alea M, Muñoz-Couselo E, Garcia-Patos V, Recio JA.
BRAF activation by metabolic stress promotes glycolysis sensitizing NRASQ61-mutated melanomas to targeted therapy
Nat Commun. 2022 Nov 19;13(1):7113
DOI: doi: 10.1038/s41467-022-34907-0
IF: 17.690

Gomez GVB, Lourenço GJ, Monteiro LMO, Rocha RS, Fernández KAM, Recio JA, Torricelli C, Coser LO, Oliveira ALR, Carron J, Moraes AM, Lima CSP.
Association of JAK/STAT genetic variants with cutaneous melanoma
Front Oncol. 2022 Aug 2;12:943483
DOI: doi: 10.3389/fonc.2022.943483
IF: 6.244

Solé C, Domingo S, Penzo E, Moliné T, Porres L, Aparicio G, Ferrer B, Cortés-Hernández J.
Downregulation of miR-885-5p Promotes NF-κB Pathway Activation and Immune Recruitment in Cutaneous Lupus Erythematosus
J Invest Dermatol. 2023 Feb;143(2):209-219.e13.
DOI: doi: 10.1016/j.jid.2022.08.036
IF: 7.590

Gómez-Tomás Á, Bouwes Bavinck JN, Genders R, González-Cruz C, de Jong E, Arron S, García-Patos V, Ferrándiz-Pulido C.
External Validation of the Skin and UV Neoplasia Transplant Risk Assessment Calculator (SUNTRAC) in a Large European Solid Organ Transplant Recipient Cohort
JAMA Dermatol. 2023 Jan 1;159(1):29-36.
DOI: doi: 10.1001/jamadermatol.2022.4820.
IF: 11.816

Suñer C, Ubals M, Tarín-Vicente EJ, Mendoza A, Alemany A, Hernández-Rodríguez Á, Casañ C, Descalzo V, Ouchi D, Marc A, Rivero À, Coll P, Oller X, Miguel Cabrera J, Vall-Mayans M, Dolores Folgueira M, Ángeles Melendez M, Agud-Dios M, Gil-Cruz E, Paris de Leon A, Ramírez Marinero A, Buhiichyk V, Galván-Casas C, Paredes R, Prat N, Sala Farre MR, Bonet-Simó JM, Farré M, Ortiz-Romero PL, Clotet B, García-Patos V, Casabona J, Guedj J, Cardona PJ, Blanco I; Movie Group; Marks M, Mitjà O
Viral dynamics in patients with monkeypox infection: a prospective cohort study in Spain
Lancet Infect Dis. Apr;23(4):445-453.
DOI: doi: 10.1016/S1473-3099(22)00794-0
IF: 71.421

Oncogene-mediated intratumoral immune-cell populations at different organs as biomarkers of immunotherapy response
Principal Investigator: Juan Angel Recio Conde
Agency: Instituto de Salud Carlos III
Funding: 341,220 €
Period: 01/01/2021 - 31/12/2023

p38alpha in control of UV-induced melanoma development
Principal Investigator: Juan Angel Recio Conde
Agency: Fundacion Ramon Areces
Funding: 129,371 €
Period: 31/01/2019 - 31/01/2022

Molecular mechanisms in melanoma
Principal Investigator: Juan Angel Recio Conde
Agency: Generalitat de Catalunya - 2021 SGR 00653
Funding: 60,000 €
Period: 31/01/2021 - 31/01/2023